头孢吡肟-他尼硼巴坦参考肉汤微量稀释MIC方法的建立
本研究建立并验证了头孢吡肟-他尼硼巴坦(他尼硼巴坦固定4 µg/mL)的参考肉汤微量稀释MIC方法,符合CLSI M07和ISO 20776-1:2019标准。在9个临床微生物实验室参与的CLSI M23 Tier 2研究中,确定产CTX-M-15大肠埃希菌NCTC 13353适合作为质控菌株,其头孢吡肟(≥64 µg/mL)与头孢吡肟-他尼硼巴坦(0.12-1 µg/mL)MIC范围不重叠。99.6%(269/270)的MIC结果在质控范围内;监测研究和CERTAIN-1 III期临床研究两个中心实验室的质控值在范围内比例分别为100%(79/79)和98.0%(98/100)。仅当接种菌量超过CLSI M07标准(2-8×10^5 CFU/mL)时MIC值才升高至质控范围以上。
要点
- 头孢吡肟-他尼硼巴坦参考肉汤微量稀释法他尼硼巴坦固定4 µg/mL。
- 产CTX-M-15大肠埃希菌NCTC 13353适合作常规质控,两药MIC范围不重叠。
- 仅接种菌量≥5×10^6 CFU/mL时MIC值超出质控范围,方法稳健可靠。
核心结论
- 头孢吡肟-他尼硼巴坦肉汤微量稀释参考MIC方法按批准标准执行时具有稳健性和可靠性。
研究设计与样本
- CLSI M23 Tier 2研究,纳入9个临床微生物实验室,评估质控菌株及方法在不同条件下的表现。
主要发现
- 99.6%(269/270)的头孢吡肟-他尼硼巴坦MIC结果在确定的质控范围内。
- 监测研究中100%(79/79)的质控值在范围内。
- CERTAIN-1 III期临床研究两个中心实验室98.0%(98/100)的质控值在范围内。
- 仅接种菌量≥5×10^6 CFU/mL超过CLSI M07标准(2-8×10^5 CFU/mL)时MIC值升高至质控范围以上。
关键数值与推荐
- 质控菌株产CTX-M-15大肠埃希菌NCTC 13353的头孢吡肟MIC范围≥64 µg/mL。
- 同一质控菌株的头孢吡肟-他尼硼巴坦MIC范围为0.12-1 µg/mL。
- CLSI M07标准接种菌量为2-8×10^5 CFU/mL。
临床怎么用
- 按CLSI M07和ISO 20776-1:2019标准执行头孢吡肟-他尼硼巴坦肉汤微量稀释MIC检测。
- 使用产CTX-M-15大肠埃希菌NCTC 13353作为常规质控菌株,同时监控头孢吡肟活性和他尼硼巴坦酶抑制。
局限性
- 原文未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The investigational β-lactam/β-lactamase inhibitor combination cefepime-taniborbactam is intended as therapy for serious infections caused by Gram-negative pathogens resistant to third-generation cephalosporins and carbapenems. Establishing a susceptibility testing reference method for cefepime-taniborbactam that conforms to the Clinical Laboratory Standards Institute (CLSI) M07 and International Standards Organization 20776-1:2019 standards is necessary to inform patient care. This study describes the reference broth microdilution MIC method for cefepime-taniborbactam (taniborbactam fixed at 4 µg/mL). In a CLSI M23 Tier 2 study that included nine clinical microbiology laboratories, the CTX-M-15-producer Escherichia coli NCTCC 13353 was determined to be appropriate for routine quality control (QC) as ranges for cefepime (≥64 µg/mL) and cefepime-taniborbactam (0.12 to 1 µg/mL) were non-overlapping, thereby simultaneously controlling for cefepime antibacterial activity and taniborbactam β-lactamase inhibition. Of the cefepime-taniborbactam MIC results obtained, 99.6% (269/270) were within the identified QC range; similarly, 100% (79/79) and 98.0% (98/100) of the QC values from a surveillance study and from the two central microbiology laboratories of the CERTAIN-1 Phase 3 clinical study (clintrials.gov identifier NCT03840148) were in range, respectively. Modifications to the standard medium (pH, cation content, or supplementation with human serum, albumin, polysorbate-80, or pulmonary surfactant) or assay parameters (inoculum density, incubation duration, and atmosphere) revealed that only inoculum titers (e.g., ≥5 × 106 CFU/mL) exceeding the CLSI M07 standard (2-8 × 105 CFU/mL) increased MIC values above the QC range. These results demonstrate the robustness and reliability of the cefepime-taniborbactam broth microdilution MIC reference method when performed following the approved standards. IMPORTANCE: This study focuses on a new antibiotic combination called cefepime-taniborbactam that is being developed to treat serious infections caused by bacteria that are often resistant to current treatments. To make sure this new antibiotic combination can be used safely and effectively once it has been approved for clinical use, we developed a standardized laboratory method to measure its activity against certain bacteria that are widely used during quality control testing. The method was assessed in multiple labs and proved to be reliable, accurate, and consistent. It also held up well under different testing conditions, showing that it is a dependable tool for guiding treatment decisions. This is an important step in meeting the challenge of antibiotic-resistant infections since it will help clinicians evaluate cefepime-taniborbactam as a potential treatment option as they strive to improve the care of patients suffering from serious infections.
引用
- Belley A, Cusick SM, Pevear DC, et al. Establishing the reference broth microdilution MIC method for cefepime-taniborbactam. J Clin Microbiol. 2025. PMID: 40827922. doi:10.1128/jcm.00661-25
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。